Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2016-01-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse.
The primary outcome variable between the two techniques will be length of hospitalization after initiation of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
NCT05022459
Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A
NCT03432520
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
NCT00221195
Study of a Gene Therapy Treatment for Hemophilia A
NCT06297486
Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography
NCT03002480
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
tPA alone
tPA alone used to treat empyema
tPA alone
tPA plus dornase
tPA plus dornase used to treat empyema
tPA plus dornase
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tPA alone
tPA plus dornase
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Septation or loculation seen on ultrasound or computed tomography or
* Greater than 10,000 white blood cells identified on pleural tap
Exclusion Criteria
* Secondary diagnosis or condition that will keep them in the hospital beyond the empyema
* Existing contraindications to chest tube
* Documented allergy to one of the study medications
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Children's Mercy Hospital Kansas City
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shawn St. Peter
Assoc Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shawn D St. Peter, MD
Role: PRINCIPAL_INVESTIGATOR
Children's Mercy Hospital and Clinics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Mercy Hospital
Kansas City, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12120552
Identifier Type: OTHER
Identifier Source: secondary_id
12120552
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.